1. Home
  2. AVB vs DGX Comparison

AVB vs DGX Comparison

Compare AVB & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVB

AvalonBay Communities Inc.

HOLD

Current Price

$181.20

Market Cap

25.1B

Sector

Real Estate

ML Signal

HOLD

Logo Quest Diagnostics Incorporated

DGX

Quest Diagnostics Incorporated

HOLD

Current Price

$182.89

Market Cap

20.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVB
DGX
Founded
1978
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1B
20.5B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
AVB
DGX
Price
$181.20
$182.89
Analyst Decision
Buy
Buy
Analyst Count
15
15
Target Price
$208.90
$194.07
AVG Volume (30 Days)
985.1K
1.1M
Earning Date
10-29-2025
10-21-2025
Dividend Yield
3.86%
1.75%
EPS Growth
12.03
14.49
EPS
8.20
8.51
Revenue
$3,065,608,000.00
$10,850,000,000.00
Revenue This Year
$3.39
$12.37
Revenue Next Year
$4.57
$3.51
P/E Ratio
$22.09
$21.43
Revenue Growth
6.50
13.74
52 Week Low
$166.73
$148.70
52 Week High
$234.54
$197.55

Technical Indicators

Market Signals
Indicator
AVB
DGX
Relative Strength Index (RSI) 52.05 47.10
Support Level $180.08 $184.18
Resistance Level $183.60 $193.35
Average True Range (ATR) 2.42 3.51
MACD 0.78 -0.28
Stochastic Oscillator 68.31 16.06

Price Performance

Historical Comparison
AVB
DGX

About AVB AvalonBay Communities Inc.

AvalonBay Communities owns a portfolio of 295 apartment communities with almost 90,000 units and is developing 20 additional properties with approximately 7,300 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Share on Social Networks: